论文部分内容阅读
目的:探究扶正化瘀胶囊配合阿福德韦酯治疗肝纤维化的临床效果。方法:选取100例肝纤维化患者,随机分为研究组和对照组各50例。研究组患者应用扶正化瘀胶囊联合阿福德韦酯进行治疗,对照组患者仅应用阿福德韦酯进行治疗。观察比较两组患者治疗前后的肝纤维化指标、门静脉内径及脾脏厚度的变化。结果:治疗前,两组患者肝纤维化指标比较无统计学差异(P>0.05),治疗后,研究组患者血清透明质酸(HA)、层黏蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)、血清组织基质金属蛋白酶抑制酶-2(TIMP-2)及血清羟脯氨酸(HYP)等各项肝纤维化指标均优于对照组,门静脉内径及脾脏厚度均小于对照组,差异均具有统计学意义(P<0.01)。两组患者均未出现严重不良反应。结论:扶正化瘀胶囊配合阿福德韦酯治疗肝纤维化患者可有效改善肝纤维化指标、缩小门静脉内径及脾脏厚度,治疗效果更显著。
Objective: To investigate the clinical effect of Fuzheng Huayu capsule combined with adefovir dipivoxil on liver fibrosis. Methods: 100 patients with liver fibrosis were randomly divided into study group and control group, 50 cases each. Patients in the study group were treated with Fuzhenghuayu capsule combined with adefovir dipivoxil, while patients in the control group were treated with only adefovir dipivoxil. The changes of liver fibrosis index, portal vein diameter and spleen thickness before and after treatment were observed and compared between the two groups. Results: Before treatment, there was no significant difference between the two groups (P> 0.05). After treatment, the levels of serum hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen ), Collagen Ⅳ (C Ⅳ), tissue inhibitor of matrix metalloproteinase 2 (TIMP-2) and serum hydroxyproline (HYP) were significantly higher than those in control group. The diameter of portal vein and the thickness of spleen All less than the control group, the differences were statistically significant (P <0.01). No serious adverse reactions occurred in both groups. Conclusion: Fuzhenghuayu capsule combined with adefovir dipivoxil treatment of liver fibrosis patients can effectively improve liver fibrosis indicators, reduce the diameter of the portal vein and spleen thickness, the treatment effect is more significant.